New trends in non-pharmacological approaches for cardiovascular disease: Therapeutic ultrasound

Liu, Tianshu; Shi, Jiawei; Fu, Yanan; Zhang, Yichan; Bai, Ying; He, Shukun; Deng, Wenhui; Jin, Qiaofeng; Chen, Yihan; Fang, Lingyun; He, Lin; Li, Yuman; Yang, Yali; Zhang, Li; Lv, Qing; Wang, Jing; Xie, Mingxing

doi:10.1016/j.tcm.2022.04.005

Cited by 5 publications

(3 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 D) of hearts in LIPUS groups were significantly attenuated, specifically in LIPUS-0.35 MPa group. Ultrasound wave may produce certain cavitation efficiency and thermal efficiency [ 21 ]. Spleen HE staining is to observe the safety of focused ultrasound stimulation on target organs, which shows whether the spleen has pathological damage such as hemorrhage and cell necrosis.…”

Section: Resultsmentioning

confidence: 99%

Noninvasive ultrasound stimulation to treat myocarditis through splenic neuro-immune regulation

Liu

Shi

et al. 2023

J Neuroinflammation

Self Cite

View full text Add to dashboard Cite

Background The cholinergic anti-inflammatory pathway (CAP) has been widely studied to modulate the immune response. Current stimulating strategies are invasive or imprecise. Noninvasive low-intensity pulsed ultrasound (LIPUS) has become increasingly appreciated for targeted neuronal modulation. However, its mechanisms and physiological role on myocarditis remain poorly defined. Methods The mouse model of experimental autoimmune myocarditis was established. Low-intensity pulsed ultrasound was targeted at the spleen to stimulate the spleen nerve. Under different ultrasound parameters, histological tests and molecular biology were performed to observe inflammatory lesions and changes in immune cell subsets in the spleen and heart. In addition, we evaluated the dependence of the spleen nerve and cholinergic anti-inflammatory pathway of low-intensity pulsed ultrasound in treating autoimmune myocarditis in mice through different control groups. Results The echocardiography and flow cytometry of splenic or heart infiltrating immune cells revealed that splenic ultrasound could alleviate the immune response, regulate the proportion and function of CD4+ Treg and macrophages by activating cholinergic anti-inflammatory pathway, and finally reduce heart inflammatory injury and improve cardiac remodeling, which is as effective as an acetylcholine receptor agonists GTS-21. Transcriptome sequencing showed significant differential expressed genes due to ultrasound modulation. Conclusions It is worth noting that the ultrasound therapeutic efficacy depends greatly on acoustic pressure and exposure duration, and the effective targeting organ was the spleen but not the heart. This study provides novel insight into the therapeutic potentials of LIPUS, which are essential for its future application. Graphical Abstract

show abstract

Section: Resultsmentioning

confidence: 99%

Noninvasive ultrasound stimulation to treat myocarditis through splenic neuro-immune regulation

Liu

Shi

et al. 2023

J Neuroinflammation

Self Cite

View full text Add to dashboard Cite

show abstract

“…[ 135 ] Besides ultrasound imaging, noninvasive ultrasound therapy, attributed to its superior tissue penetration capabilities compared to light‐based stimulation and its capacity to minimize adverse effects on surrounding healthy tissues, has undergone extensive basic and preclinical research in the context of cardiovascular diseases, spanning ischemic heart disease, heart failure, myocarditis, arrhythmias, and hypertension, resulting in notable advancements. [ 136 ] Among these, two ultrasound‐targeted therapies—sonothrombolysis and ultrasound‐mediated flow augmentation or sonoperfusion, have progressed into clinical trials. [ 137 ] In atherosclerosis, the theranostic nanosystems of IONPs associated with ultrasound therapy have been investigated and reported.…”

Section: Iron Oxide Nanoparticle‐based Theranostic Nanomedicine Using...mentioning

confidence: 99%

Advances in Atherosclerosis Theranostics Harnessing Iron Oxide‐Based Nanoparticles

Wang,

He,

Mao

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Atherosclerosis, a multifaceted chronic inflammatory disease, has a profound impact on cardiovascular health. However, the critical limitations of atherosclerosis management include the delayed detection of advanced stages, the intricate assessment of plaque stability, and the absence of efficacious therapeutic strategies. Nanotheranostic based on nanotechnology offers a novel paradigm for addressing these challenges by amalgamating advanced imaging capabilities with targeted therapeutic interventions. Meanwhile, iron oxide nanoparticles have emerged as compelling candidates for theranostic applications in atherosclerosis due to their magnetic resonance imaging capability and biosafety. This review delineates the current state and prospects of iron oxide nanoparticle‐based nanotheranostics in the realm of atherosclerosis, including pivotal aspects of atherosclerosis development, the pertinent targeting strategies involved in disease pathogenesis, and the diagnostic and therapeutic roles of iron oxide nanoparticles. Furthermore, this review provides a comprehensive overview of theranostic nanomedicine approaches employing iron oxide nanoparticles, encompassing chemical therapy, physical stimulation therapy, and biological therapy. Finally, this review proposes and discusses the challenges and prospects associated with translating these innovative strategies into clinically viable anti‐atherosclerosis interventions. In conclusion, this review offers new insights into the future of atherosclerosis theranostic, showcasing the remarkable potential of iron oxide‐based nanoparticles as versatile tools in the battle against atherosclerosis.

show abstract

“…Several studies have shown the great potential of ultrasonic neuromodulation to treat various neurological or psychiatric disorders such as essential tremor [9], epilepsy [10], Alzheimer's disease [11], Parkinson's disease [12], and depression [13]. In addition, many studies have reported the case of low-intensity focused ultrasound (LIFU) stimulation to treat cardiovascular disease recently [14]. A previous study by our group showed that LIFU stimulation of the ventrolateral periaqueductal gray (VLPAG) in spontaneously hypertensive rats (SHRs) model for 20 min every day for one week can lead to a sustained reduction in blood pressure and inhibit sympathetic activity [15].…”

Section: Introductionmentioning

confidence: 99%

The sustainable antihypertensive and target organ damage protective effect of transcranial focused ultrasound stimulation in spontaneously hypertensive rats

Li¹,

Zhang²,

Cao³

et al. 2023

Journal of Hypertension

View full text Add to dashboard Cite

In this study, we aimed to investigate the sustainable antihypertensive effects and protection against target organ damage caused by low-intensity focused ultrasound (LIFU) stimulation and the underlying mechanism in spontaneously hypertensive rats (SHRs) model.Methods and results: SHRs were treated with ultrasound stimulation of the ventrolateral periaqueductal gray (VlPAG) for 20 min every day for 2 months. Systolic blood pressure (SBP) was compared among normotensive Wistar-Kyoto rats, SHR control group, SHR Sham group, and SHR LIFU stimulation group. Cardiac ultrasound imaging and hematoxylin-eosin and Masson staining of the heart and kidney were performed to assess target organ damage. The c-fos immunofluorescence analysis and plasma levels of angiotensin II, aldosterone, hydrocortisone, and endothelin-1 were measured to investigate the neurohumoral and organ systems involved. We found that SBP was reduced from 172 AE 4.2 mmHg to 141 AE 2.1 mmHg after 1 month of LIFU stimulation, P < 0.01. The next month of treatment can maintain the rat's blood pressure at 146 AE 4.2 mmHg at the end of the experiment. LIFU stimulation reverses left ventricular hypertrophy and improves heart and kidney function. Furthermore, LIFU stimulation enhanced the neural activity from the VLPAG to the caudal ventrolateral medulla and reduced the plasma levels of ANGII and Aldo. Conclusion:We concluded that LIFU stimulation has a sustainable antihypertensive effect and protects against target organ damage by activating antihypertensive neural pathways from VLPAG to the caudal ventrolateral medulla and further inhibiting the renin-angiotensin system (RAS) activity, thereby supporting a novel and noninvasive alternative therapy to treat hypertension.

show abstract

New trends in non-pharmacological approaches for cardiovascular disease: Therapeutic ultrasound

Cited by 5 publications

References 98 publications

Noninvasive ultrasound stimulation to treat myocarditis through splenic neuro-immune regulation

Noninvasive ultrasound stimulation to treat myocarditis through splenic neuro-immune regulation

Advances in Atherosclerosis Theranostics Harnessing Iron Oxide‐Based Nanoparticles

The sustainable antihypertensive and target organ damage protective effect of transcranial focused ultrasound stimulation in spontaneously hypertensive rats

Contact Info

Product

Resources

About